Authors
Latest:
NSCLC: Final ThoughtsThe discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) ends as each expert discusses their final thoughts.
Latest:
Dr Obeng-Gyasi on Neighborhood Opportunity and Mortality in Breast CancerSamilia Obeng-Gyasi, MD, MPH, discusses a retrospective study on neighborhood opportunity and all-cause mortality in patients with breast cancer.
Latest:
Dr. D'Agostino on Factors for Unsustained MRD Negativity in Multiple MyelomaMattia D'Agostino, MD, discusses factors that could lead to unsustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma who are transplant eligible.
Latest:
Mentoring Oncologists in the Era of Social DistancingMentoring is critically important to the development of young academic hematology/oncology trainees.
Latest:
Dr. Patil on Unmet Needs With the Use of Immunotherapy in NSCLCPradnya D. Patil, MD, FACP, discusses unmet needs that remain to be addressed with the use of immunotherapy in patients with non–small cell lung cancer.
Latest:
Dr. Goldkorn on the Methods Used to Predict Chemotherapy Benefit in Bladder CancerAmir Goldkorn, MD, discusses the methods utilized to predict chemotherapy benefit in bladder cancer.
Latest:
Dr. Moreira on Launching the Global COVID-19 Observatory and Resource Center for Childhood CancerDaniel Moreira, MD, discusses the rationale for launching the Global COVID-19 Observatory and Resource Center for Childhood Cancer.
Latest:
Dr McLellan on the Association Between A Skin Bacterium and Severe Acute Radiation DermatitisBeth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.
Latest:
Progress in SCLC: From Deadly to Cure?Millie Das, MD, of Stanford Cancer Center, discusses the progress in small cell lung cancer treatment.
Latest:
Dr. Schmid on Next Steps for the RACE IT Trial in Urothelial CarcinomaSebastian C. Schmid, MD, discusses the future of the phase 2 RACE IT trial in urothelial carcinoma.
Latest:
Dr Biachi on the Growing Treatment Landscape in HCCTiago Biachi, MD, PhD, discusses the growing treatment landscape for patients with hepatocellular carcinoma.
Latest:
Women in Oncology: Leukemia Therapies in Humans, for HumansJudith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..
Latest:
Franklin on Strategies to Ameliorate the Effect of Social Determinants on CRC Screening RatesIsabelle Franklin, discusses strategies healthcare providers can implement to address or ameliorate disparities in place that are affecting screening rates in colorectal cancer.
Latest:
Dr Anders on the Investigation of CCR4 Antagonists in Advanced CancersRobert Albert Anders, MD, PhD, discusses the rationale for developing CCR4 antagonists for use in patients with advanced cancers, including lymphoma and non–small cell lung cancer.
Latest:
Future Management of Chronic Myeloid LeukemiaClosing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.
Latest:
Dr Jimenez on the Radiation Treatment Paradigm in Breast CancerRachel Jimenez, MD, discusses unmet needs in radiation treatment for patients with breast cancer.
Latest:
Dr. Kazmi on Key Treatment Considerations for Young-Onset CRCSyed Kazmi, MD, an oncologist at The University of Texas Southwestern Medical Center, discusses key treatment considerations for young patients with onset colorectal cancer.
Latest:
Unmet Needs and Treatment Trajectory for Patients Diagnosed with Ph+ ALLWith their final thoughts, medical experts share unmet needs in the treatment landscape of Ph+ acute lymphoblastic leukemia.
Latest:
Dr. Casablanca on the Integration of Pembrolizumab in Recurrent or Metastatic Cervical CancerYovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.
Latest:
Dr. Iagaru on Advancements in PSMA-PET Imaging for Prostate CancerAndrei H. Iagaru, MD, discusses key points from his presentation on the use of novel vs conventional imaging to manage metastatic hormone-sensitive prostate cancer.
Latest:
Dr. Balzarotti on the Challenges of Treating Elderly DLBCLMonica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.
Latest:
Dr Wolf on Biomarkers Predicting Responses to Immunotherapy in Breast CancerDenise M. Wolf, PhD, discusses research into biomarkers predicting responses to immunotherapy in the phase 2 I-SPY2 trial in patients with early-stage breast cancer.
Latest:
Dr. Kundranda on the Sequencing of Second-Line Therapies in HCCMadappa Kundranda, MD, PhD, discusses the sequencing of second-line therapies in hepatocellular carcinoma.
Latest:
Dr. Michalski on the Goals ASTRO in Radiation OncologyJeff Michalski, MD, MBA, FASTRO, discusses the goals of the American Society for Radiation Oncology in radiation oncology.
Latest:
Immunotherapy Paves Path for New Standards of Care in Gastroesophageal CancersIt is crucial to understand and interpret the results from the landmark clinical trials in the context of recent FDA approvals in gastroesophageal cancers.
Latest:
Dr. Chatzkel on the Rationale for the IMMCO-1 trial in mCRPC and Other Immunologically Cold TumorsJonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.
Latest:
Best Practices for Virtual Conference PresentationsAs the autumn and winter conference season approaches, Curtis Lachowiez, MD, reflects on the impact 2020 left on the field of oncology.
Latest:
Using Systemic Therapy to Treat HER2+ Breast CancerClosing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.
Latest:
Dr Patel on the Evolving Use of Neoadjuvant PD-1 Inhibitors in CSCCVishal Patel, MD, FAAD, FACMS, discusses the evolving use of neoadjuvant and adjuvant PD-1 inhibition in cutaneous squamous cell carcinoma.
